From Indirect Evidence to Head-to-Head Trials in Anticoagulation: Clinical Implications of the COBRRA Moment in DOAC Treatment
Journal of Cardiovascular Pharmacology and Therapeutics · 2026-03 · 31
DOI: 10.1177/10742484261440329 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Cardiovascular Pharmacology and Therapeutics, online erschienen am 31.03.2026. Verfasst von Andrej Belancic und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic and Clinical Pharmacology and Toxicology, University of Rijeka, Rijeka, Croatia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Basic and Clinical Pharmacology and Toxicology, University of Rijeka, Rijeka, Croatia.
- Department of Cardiovascular Diseases, University Hospital of Split (KBC Split), Split, Croatia.
- Department of Pathophysiology, University of Split School of Medicine, Split, Croatia.
ORCID-Profile: Andrej Belancic, Josip Andelo Borovac
Zitieren
APA
Belancic, A., & Borovac, J. A. (2026). From Indirect Evidence to Head-to-Head Trials in Anticoagulation: Clinical Implications of the COBRRA Moment in DOAC Treatment. Journal of Cardiovascular Pharmacology and Therapeutics, 31. https://doi.org/10.1177/10742484261440329
Vancouver
Belancic A, Borovac JA. From Indirect Evidence to Head-to-Head Trials in Anticoagulation: Clinical Implications of the COBRRA Moment in DOAC Treatment. Journal of Cardiovascular Pharmacology and Therapeutics. 2026;31. doi:10.1177/10742484261440329
BibTeX
@article{Belancic2026,
author = {Belancic, Andrej and Borovac, Josip Andelo},
title = {From Indirect Evidence to Head-to-Head Trials in Anticoagulation: Clinical Implications of the COBRRA Moment in DOAC Treatment},
journal = {Journal of Cardiovascular Pharmacology and Therapeutics},
year = {2026},
volume = {31},
doi = {10.1177/10742484261440329}
}
EUVIMED